Search results
CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and...
Morningstar· 6 days agoLeading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel ...
...Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails - AstraZeneca...
Benzinga· 2 days agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 3 days agoThe FDA approved AstraZeneca’s AZN type-II diabetes (T2D) medicine, Farxiga, for pediatric patients....
AbbVie, FutureGen in License Pact for Inflammatory Bowel Disease Drug
Market Watch· 4 days agoPublished: June 13, 2024 at 9:03 a.m. ETShareResizeBy Colin KellaherAbout Dow Jones NewswiresDow Jones Newswires is a market-moving financial and business news source, used by wealth managers ...
EHA 2024: Roche’s Columvi competes in BiTE battle with positive results in DLBCL
Pharmaceutical Technology via Yahoo Finance· 5 hours agoBased on the latest STARGLO trial results, there is potential to extend Columvi into earlier lines...
Digital Medicine Society partners with pharma giants for new digital endpoints project
FierceBiotech· 4 days agoAbbvie, Merck, Roche, Genentech, Regeneron, Sanofi and other big names in biopharma have signed on...
8 Lesser-Known Stocks To Bet on This Summer
GOBankingRates via Yahoo Finance· 6 days agoThe stock market has been on a roll lately and some stocks have been skyrocketing. Artificial intelligence darling Nvidia is at the forefront, shooting...
Atezolizumab Consolidation Impresses in High-Risk DLBCL
MedPage Today· 3 days agoPostchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year...
SMC recommends first injectable bispecific for aggressive blood cancer
BioPharma-Reporter· 7 days agoThis approval introduces the first subcutaneous bispecific antibody treatment for this aggressive...
What's in a Name: Defining Difficult-to-Treat axSpA and PsA
Medscape· 3 days agoDespite an expanding arsenal of disease-modifying antirheumatic drugs (DMARDs), many patients with...